Analysis: After Roche merger, biotech tail wags big pharma dog
ZURICH (Reuters) - When Roche paid $46.8 billion in 2009 to gain full ownership of Genentech, fears were rife that the arrival of the Swiss men in suits would stifle the free-wheeling innovative culture at the California-based biotech. Three years on, however, the jeans-wearing scientists in San Francisco have proven they are the ones driving the drugs pipeline of the 116-year-old Basel-based pharma giant, casting a shadow over Roche's own research operations. ...
Source: news.yahoo.com
No comments:
Post a Comment